Skip to main content

Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019

Written by Customer Service on . Posted in Public Companies.

Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) — Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented with the “Poster of the Day” award at the renowned Fall Clinical Dermatology Conference in Las Vegas from October 17 to 20, 2019 for its latest Phase III clinical trial.
During the conference, the company presented four scientific posters on the application of photodynamic therapy (PDT) for the treatment of actinic keratoses (AK) and basal cell carcinomas. The poster presentation of the results of the Phase III clinical trial on the safety and efficacy of conventional PDT with BF-200 ALA (development name for Ameluz®) and the BF-RhodoLED® lamp for the treatment of mild to severe AKs on the extremities or the trunk/neck (original title: Photodynamic therapy with BF-200 ALA for the treatment of mild to severe actinic keratosis on extremities and trunk/neck: Results of a randomized Phase III trial) was selected “Poster of the Day” by the attending dermatologists.“The great interest of US-dermatologists at the conference confirms the growth of the PDT market in the US. We are proud of the recognition of our positive data from our latest phase III trial with BF-200 ALA received,” commented Prof. Dr. Hermann Lübbert, Chief Executive Officer of Biofrontera. “The annual Fall Clinical Dermatology Conference offers us the opportunity to network with leading dermatologists in the US and inform them about our products.”The annual Fall Clinical Dermatology Conference is the second largest conference for dermatologists in the US and took place from October 17 to 20, 2019 in Las Vegas.-End-About Biofrontera:Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets Xepi™, a prescription medication for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.